Clin2
NCT06254326Possibly a fitRecruiting

Immune cell therapy for recurrent oligodendroglioma

Recurrent OligodendrogliomaProgressive Oligodendroglioma

Part of Brain & nervous system, Cancer clinical trials.

This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years to 89 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have a confirmed oligodendroglioma (IDH-mutant, 1p/19q co-deleted) that has returned or worsened after radiation therapy.
  • You are well enough to have surgery or a biopsy.
  • You are not taking more than 4 mg of dexamethasone (a steroid) per day.
  • You do not have active infections or serious health conditions that would interfere with the treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06514898Recruiting· Phase 1
Personalized cell therapy for recurrent medulloblastoma

This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.

Washington D.C., District of Columbia
NCT03896568Recruiting· Phase 1
Trial of stem cell therapy for recurrent high-grade brain tumors

This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.

Houston, Texas
NCT07172178Not yet recruiting· Early Phase 1
Immune cell therapy for recurrent malignant brain tumor

This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.

NCT07318818Recruiting· Phase 1/Phase 2
Revised cell therapy for recurrent brain cancer

This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.

Beijing
NCT06815029Recruiting· Phase 1
Modified immune cells for recurrent brain cancer

This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.

Duarte, California
NCT07472790Not yet recruiting· Phase 1
Virus therapy with immunotherapy for recurrent brain tumor

This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.

Beijing, Chaoyang District

Hear when a new Recurrent Oligodendroglioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.